The nomination committee’s proposal of board of directors in ADDvise Group AB (publ)

04-02-2022   Regulatory press release

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 6 May 2022, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Erland Pontusson and Johanne Brændgaard as members of the board of directors. In addition, the nomination committee proposes the election of Anna Ljung. It is proposed that Staffan Torstensson is re-elected chairman of the board of directors. Rikard Akhtarzand, CEO of the company, has declined re-election to separate the roles of CEO and board member, since one of the board’s tasks, amongst others, is to evaluate the CEO.

Anna Ljung has a master’s degree in Economic and Business Administration from Stockholm School of Economics. Anna Ljung has more than 15 years of experience from the pharmaceutical industry. She is currently serving as CEO of Moberg Pharma AB, chairman of the board of OncoZenge AB and board member of Saniona AB. In addition, Anna Ljung has previously been serving as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB. Anna Ljung is independent in relation to the company, its management, and its largest shareholders.

A presentation of the current members of the board of directors is available on ADDvise Group’s website.

The nomination committee's full proposals to the AGM 2022 will be published in connection with the notice to the AGM 2022.

The nomination committee of ADDvise Group for the AGM 2022 consists of Per-Anders Tammerlöv (chairman of the nomination committee) appointed by Rikard Akhtarzand, shareholder through direct and indirect ownership, Per Åhlgren, shareholder through indirect ownership, Magnus Vahlquist, shareholder through direct and indirect ownership and Staffan Torstensson, chairman of ADDvise Group AB. The members of the nomination committee jointly represent approximately 36 per cent of the votes in the company.  

For further information, please contact:

Hanna Myhrman, General Counsel
+46 709 – 82 92 23

hanna.myhrman@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise receives order from Cadwell Industries worth approximately USD 1.7 million

Regulatory

ADDvise Group AB’s subsidiary Merit Cables Inc has received an order from Cadwell Industries, a company specialized in electrodes, consumables, supplies, and accessories for neurology, worth approximately USD 1.7 million. The order involves wires for electrodiagnostic supplies such as EEG, EMG and ultrasound for measuring and evaluating electrical brain and muscle activity. Delivery of the…

ADDvise acquires Seebreath AB

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

Interim report January 1 – March 31 2022

Regulatory

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…